Back to MW MARSHALL WACE, LLP

TCRXTCRX
11 quarters

Position history for MWMARSHALL WACE, LLP's holdings in TSCAN THERAPEUTICS INC

MARSHALL WACE, LLP holds 687,364 shares of TCRX (TSCAN THERAPEUTICS INC), worth $673,616 as of 2026-Q2. The position was increased (+189.6% shares). TCRX represents 0.0% of MARSHALL WACE, LLP's portfolio.

Current Value

$673,616

Current Shares

687,364

Total Value Change

+$29,104

Total Shares Change

+576,813

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
687,364
+189.6%
$673,6160.0%$0.98
40
2026-Q1
Decreased
237,346
-30.0%
$239,7190.0%$1.03
0
2025-Q4
Increased
339,240
+627.5%
$339,2400.0%$1.03
38
2025-Q3
Decreased
46,630
-13.1%
$84,8670.0%$1.74
0
2025-Q2
New
53,678
-
$77,8330.0%$1.40
29
2025-Q1
Exited
0
-100.0%
$00.0%$1.35
0
2024-Q4
Decreased
43,969
-73.4%
$133,6660.0%$3.00
0
2024-Q3
Decreased
165,160
-46.3%
$822,4970.0%$5.04
0
2024-Q2
Increased
307,487
+60.8%
$1.8M0.0%$5.85
37
2024-Q1
Increased
191,171
+72.9%
$1.5M0.0%$7.94
38
2023-Q4
New
110,551
-
$644,5120.0%$5.83
34

Other major holders of TCRX: ADAGE CAPITAL PARTNERS GP, L.L.C., BlackRock Finance, Inc., BAKER BROS. ADVISORS LP

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used